Table 1.

Results of associations of IL1RL1 SNPs with ER visits/hospitalizations, OCS use, and “any exacerbation” per study and meta‐analysis

A.
SNP	Allele (R/E)a	ER visits/hospitalisations
		PACMAN (n = 698)			GALA II (n = 876)			SAGE (n = 525)			SLOVENIA (n = 187)			ESTATe (n = 104)			Meta‐analysis (n = 2421)
		OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	N
rs13431828	T/C	2.78 (1.11‐6.94)	.02	.04	1.45 (1.04‐2.03)	.03	.04	1.18 (0.88‐1.58)	.26	.52	1.20 (0.62‐2.35)	.57	.77	1.01 (0.18‐5.72)	.99	.99	1.32 (1.08‐1.62)	.005	.02	2412
rs1041973	A/C	1.35 (0.77‐2.37)	.30	.30
rs1420101	G/A	1.61 (1.05‐2.47)	.02	.04	1.28 (1.04‐1.58)	.02	.04	0.90 (0.69‐1.17)	.45	.60	1.09 (0.67‐1.76)	.72	.77	1.35 (0.56‐3.25)	.51	.94	1.16 (1.01‐1.34)	.03	.06	2412
rs1946131	G/A	1.47 (0.81‐2.68)	.20	.24
rs1921622	G/A	1.89 (1.18‐3.03)	.01	.04	1.30 (1.06‐1.59)	.01	.04	0.74 (0.55‐0.99)	.05	.20	0.93 (0.57‐1.51)	.77	.77				1.13 (0.97‐1.31)	.13	.17	2308
rs10204137	G/A	1.37 (0.87‐2.16)	.18	.24	1.24 (0.99‐1.56)	.06	.06	1.01 (0.76‐1.35)	.92	.92	0.75 (0.46‐1.22)	.24	.77	0.81 (0.34‐1.94)	.63	.94	1.10 (0.95‐1.29)	.18	.18	2412

B.
SNP	Allele (R/E)a	OCS use
		PACMAN (n = 720)			GALA II (n = 876)			SAGE (n = 525)			SLOVENIA (n = 187)			ESTATe (n = 104)			Meta‐analysis (n = 2421)
		OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	N
rs13431828	T/C	2.70 (1.08‐6.79)	.03	.09	1.25 (0.87‐1.79)	.23	.65	0.93 (0.68‐1.27)	.65	.70	1.60 (0.57‐4.47)	.36	.90	1.15 (0.46‐2.85)	.77	.77	1.13 (0.91‐1.41)	.24	.78	2412
rs1041973	A/C	1.52 (0.86‐2.66)	.15	.27
rs1420101	G/A	1.32 (0.88‐1.98)	.18	.27	1.10 (0.86‐1.40)	.49	.65	0.78 (0.57‐1.05)	.09	.20	0.95 (0.49‐1.85)	.89	.90	0.68 (0.34‐1.36)	.28	.77	0.98 (0.84‐1.16)	.90	.90	2412
rs1946131	G/A	1.08 (0.57‐2.02)	.83	.83
rs1921622	G/A	1.20 (0.78‐1.86)	.41	.49	1.10 (0.88‐1.38)	.44	.65	0.76 (0.54‐1.08)	.10	.10	0.81 (0.41‐1.59)	.54	.90				1.00 (0.84‐1.18)	.96	.96	2308
rs10204137	G/A	1.69 (1.05‐2.73)	.03	.09	1.03 (0.81‐1.32)	.80	.80	0.94 (0.69‐1.28)	.70	.70	1.04 (0.52‐2.05)	.90	.90	1.15 (0.58‐2.27)	.70	.70	1.07 (0.90‐1.27)	.39	.39	2412

C.
SNP	Allele (R/E)a	Any exacerbation
		PACMAN (n = 720)			GALA II (n = 876)			SAGE (n = 525)			SLOVENIA (n = 187)			ESTATe (n = 104)			Meta‐analysis (n = 2421)
		OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	OR (95% CI)	P	P b	N
rs13431828c	T/C	2.63 (1.33‐5.18)	.006	.03	1.63 (1.14‐2.32)	.009	.01	1.04 (0.78‐1.39)	.80	.80	1.19 (0.66‐2.12)	.73	.83	1.09 (0.47‐2.56)	.83	.86	1.31 (1.07‐1.59)	.007	.02	2412
rs1041973	A/C	1.28 (0.84‐1.96)	.26	.26
rs1420101	G/A	1.52 (1.08‐2.13)	.01	.03	1.35 (1.06‐1.72)	.01	.01	0.83 (0.63‐1.10)	.18	.36	1.05 (0.65‐1.67)	.83	.83	0.85 (0.48‐1.53)	.60	.60	1.14 (0.98‐1.32)	.07	.14	2412
rs1946131	G/A	1.37 (0.83‐2.25)	.22	.26
rs1921622	G/A	1.45 (1.03‐2.04)	.03	.04	1.35 (1.08‐1.70)	.009	.01	0.67 (0.50‐0.90)	.009	.03	0.84 (0.52‐1.35)	.47	.83				1.08 (0.92‐1.25)	.31	.31	2308
rs10204137d	G/A	1.52 (1.05‐2.18)	.02	.04	1.29 (1.00‐1.66)	.04	.04	0.91 (0.68‐1.21)	.50	.66	0.81 (0.50‐1.30)	.38	.83	0.95 (0.53‐1.70)	.86	.86	1.11 (0.96‐1.30)	.14	.18	2412

Bold‐faced results are FDR corrected significant results (P < .05). Missing values mean the SNP was not present in the study.

Abbreviations: CI, confidence interval; ER. Emergency room; OCS, oral corticosteroid; OR, odds ratio; SNP, single‐nucleotide polymorphism.

^aR = reference allele, E = effect allele.

^bFDR corrected P value.

^crs13431828 was not present in ESTATe, and rs3771180 was used as a surrogate marker (LD r ² = 1).

^drs10204137 was not present in ESTATe, and rs4988956 was used as a surrogate marker (LD r ² = 1).